{"id":"vancomycin-linezolid","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Infusion site reaction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Vancomycin works by binding to the D-alanyl-D-alanine terminus of cell wall precursors, preventing their incorporation into the bacterial cell wall. Linezolid, on the other hand, binds to the 50S ribosomal subunit, inhibiting the initiation complex of peptide formation and thereby preventing protein synthesis in bacteria.","oneSentence":"Vancomycin inhibits cell wall synthesis in Gram-positive bacteria, while Linezolid inhibits protein synthesis by binding to the 50S ribosomal subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:35.690Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of complicated skin and skin structure infections (cSSSI), including those caused by susceptible Gram-positive bacteria"},{"name":"Treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)"}]},"trialDetails":[{"nctId":"NCT07435051","phase":"PHASE3","title":"Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-05-01","conditions":"Osteomyelitis (Refractory)","enrollment":280},{"nctId":"NCT05571722","phase":"PHASE4","title":"Linezolid or Vancomycin Surgical Site Infection Prophylaxis","status":"RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2024-11-12","conditions":"Antibiotic Prophylaxis, General Surgery","enrollment":1160},{"nctId":"NCT06602245","phase":"","title":"Clearance of Antibacterial Agents During Hemoperfusion in Patients With Sepsis","status":"COMPLETED","sponsor":"Efferon JSC","startDate":"2024-10-21","conditions":"Sepsis, Septic Shock","enrollment":30},{"nctId":"NCT07204522","phase":"","title":"Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-09-22","conditions":"Febrile Neutropenia","enrollment":20},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT03176134","phase":"PHASE3","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-20","conditions":"Acute Bacterial Skin and Skin Structure Infections","enrollment":100},{"nctId":"NCT06959667","phase":"","title":"Comparative Analysis of Nemonoxacin and Other Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA) Antimicrobial Therapy in Patients With Complicated Skin and Soft Tissue Infections (cSSTI): a Retrospective Chart Review Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-04-15","conditions":"Methicillin-susceptible S. Aureus (MSSA), Anti-methicillin Resistant Staphylococcus Aureus (Anti-MRSA), Complicated Skin and Soft Tissue,cSSTI","enrollment":144},{"nctId":"NCT06729619","phase":"","title":"Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xueyan Cui","startDate":"2024-06-03","conditions":"Intracranial Infection, Central Infection","enrollment":200},{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":100},{"nctId":"NCT06336824","phase":"PHASE3","title":"Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia","status":"RECRUITING","sponsor":"Clinical Research Centre, Malaysia","startDate":"2024-06-28","conditions":"Staphylococcus Aureus Bacteremia","enrollment":290},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":"Endocarditis","enrollment":20},{"nctId":"NCT00501150","phase":"NA","title":"Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2005-09","conditions":"Gram-positive Bacterial Infections, Staphylococcal Infections","enrollment":211},{"nctId":"NCT01734694","phase":"PHASE4","title":"Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2011-10","conditions":"Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis","enrollment":100},{"nctId":"NCT02660554","phase":"NA","title":"Trial of MRSA Polymerase Chain Reaction for Pneumonia","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2016-01","conditions":"Pneumonia, Methicillin-Resistant Staphylococcus Aureus","enrollment":45},{"nctId":"NCT05354635","phase":"","title":"Therapeutic Follow-up of Antibiotics in Pediatric Intensive Care","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de la Réunion","startDate":"2022-06","conditions":"Intensive Care Units, Pediatric","enrollment":280},{"nctId":"NCT03485950","phase":"PHASE2","title":"Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-16","conditions":"Other Infectious Diseases","enrollment":100},{"nctId":"NCT04042077","phase":"PHASE3","title":"Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections","status":"TERMINATED","sponsor":"Menarini Group","startDate":"2019-09-25","conditions":"Surgical Site Infection","enrollment":268},{"nctId":"NCT04132115","phase":"","title":"Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)","status":"UNKNOWN","sponsor":"Azienda Sanitaria-Universitaria Integrata di Udine","startDate":"2019-10-01","conditions":"Therapeutic Drug Monitoring, Subarachnoid Hemorrhage, Intracerebral Hemorrhage","enrollment":104},{"nctId":"NCT04771884","phase":"","title":"Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2020-10-01","conditions":"Bacterial Meningitis, Augmented Renal Clearance","enrollment":300},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02609646","phase":"","title":"AbioKin - Antibiotic Kinetics","status":"COMPLETED","sponsor":"Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva","startDate":"2016-01","conditions":"Critical Illness, Infection","enrollment":1500},{"nctId":"NCT01792804","phase":"PHASE3","title":"Staphylococcus Aureus Bacteremia Antibiotic Treatment Options","status":"COMPLETED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2013-12","conditions":"Staphylococcus Aureus Infection","enrollment":215},{"nctId":"NCT02067390","phase":"","title":"Urinary KIM-1 After Vancomycin or Linezolid Administration","status":"TERMINATED","sponsor":"Midwestern University","startDate":"2013-09","conditions":"Acute Kidney Injury","enrollment":5},{"nctId":"NCT02426918","phase":"PHASE2","title":"Study of Debio 1450 for Bacterial Skin Infections","status":"COMPLETED","sponsor":"Debiopharm International SA","startDate":"2015-05","conditions":"Bacterial Infections","enrollment":330},{"nctId":"NCT01283581","phase":"PHASE2","title":"A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2011-01","conditions":"Skin and Subcutaneous Tissue Bacterial Infections","enrollment":256},{"nctId":"NCT02276482","phase":"PHASE3","title":"Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2015-03-25","conditions":"Skin Diseases, Infectious, Skin Diseases, Bacterial","enrollment":120},{"nctId":"NCT01756924","phase":"PHASE2","title":"Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection","status":"TERMINATED","sponsor":"Arrevus Inc.","startDate":"2012-12","conditions":"Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers","enrollment":14},{"nctId":"NCT02168816","phase":"PHASE2","title":"Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis","status":"TERMINATED","sponsor":"Loyola University","startDate":"2014-03-19","conditions":"Osteomyelitis","enrollment":30},{"nctId":"NCT01570192","phase":"PHASE2","title":"Clinical Trials to Reduce the Risk of Antimicrobial Resistance","status":"TERMINATED","sponsor":"University of Florida","startDate":"2010-09","conditions":"Bacterial Pneumonia","enrollment":43},{"nctId":"NCT03245879","phase":"NA","title":"Antibiotic Stewardship in Small Hospitals","status":"COMPLETED","sponsor":"Intermountain Health Care, Inc.","startDate":"2013-07","conditions":"Inappropriate Prescribing, Antibiotic Stewardship, Anti-Bacterial Agents","enrollment":30000},{"nctId":"NCT02732327","phase":"PHASE2","title":"Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2016-05-17","conditions":"Neoplasms, Febrile Neutropenia","enrollment":2},{"nctId":"NCT01669980","phase":"PHASE4","title":"Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-10","conditions":"Infections, Pneumonia","enrollment":40},{"nctId":"NCT01592032","phase":"PHASE4","title":"Concentration of Antimicrobials in Catheter-lock Solutions","status":"UNKNOWN","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2012-05","conditions":"Catheter-Related Infections, Bacteremia.","enrollment":125},{"nctId":"NCT00925093","phase":"PHASE1","title":"Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection","status":"WITHDRAWN","sponsor":"Aarhus University Hospital","startDate":"2011-09","conditions":"Neurosurgery","enrollment":""},{"nctId":"NCT01400867","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12","conditions":"Infections, Pediatrics","enrollment":163},{"nctId":"NCT00475891","phase":"","title":"Determination of Genetic Relatedness of Linezolid-resistant Vancomycin-resistant Enterococci (VRE) Surveillance Cultures","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2007-04","conditions":"Isolate, Linezolid","enrollment":20},{"nctId":"NCT02191475","phase":"PHASE2, PHASE3","title":"Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2014-05","conditions":"Abdominal Infection","enrollment":100},{"nctId":"NCT01561469","phase":"","title":"Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-11","conditions":"Methicillin-Resistant Staphylococcus Aureus (MRSA), Hospital-Acquired Pneumonia","enrollment":188},{"nctId":"NCT01757236","phase":"PHASE2","title":"Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection","status":"UNKNOWN","sponsor":"University Hospital, Tours","startDate":"2012-10","conditions":"Hip Prosthetic Joint Infection","enrollment":100},{"nctId":"NCT01431339","phase":"PHASE3","title":"Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2011-07","conditions":"Abscess, Wound Infection, Surgical Site Infection","enrollment":739},{"nctId":"NCT01339091","phase":"PHASE3","title":"Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Durata Therapeutics Inc., an affiliate of Allergan plc","startDate":"2011-03","conditions":"Abscess, Wound Infection, Surgical Site Infection","enrollment":573},{"nctId":"NCT01819935","phase":"","title":"Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-12","conditions":"Pneumonia","enrollment":5271},{"nctId":"NCT01551719","phase":"NA","title":"Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation","status":"WITHDRAWN","sponsor":"Federico II University","startDate":"2012-03","conditions":"Infection of Skin and/or Subcutaneous Tissue","enrollment":""},{"nctId":"NCT00087490","phase":"PHASE4","title":"Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-10","conditions":"Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA)","enrollment":1077},{"nctId":"NCT00108433","phase":"PHASE3","title":"Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections","status":"TERMINATED","sponsor":"Pfizer","startDate":"2005-09","conditions":"Bacteremia, Gram-Positive Bacterial Infections","enrollment":61},{"nctId":"NCT01564758","phase":"","title":"Post Marketing Surveillance Study on Linezolid","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-02","conditions":"Gram-Positive Bacterial Infections","enrollment":99},{"nctId":"NCT01224626","phase":"","title":"Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-05","conditions":"Vancomycin Resistance Enterococcus Faecium","enrollment":41},{"nctId":"NCT01363271","phase":"","title":"Cost Study of Linezolid Versus Vancomycin Among Previously Hospitalized Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Complicated Skin and Structure Infection, Nosocomial Pneumonia","enrollment":7260},{"nctId":"NCT01040585","phase":"","title":"Cost Effectiveness Of Linezolid In Central America","status":"WITHDRAWN","sponsor":"Pfizer","startDate":"2010-07","conditions":"Ventilator Acquired Pneumonia","enrollment":""},{"nctId":"NCT00084266","phase":"PHASE4","title":"Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-10","conditions":"Methicillin Resistant Staphylococcus Aureus (MRSA)","enrollment":1225},{"nctId":"NCT00811980","phase":"","title":"The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents","status":"COMPLETED","sponsor":"University of Utah","startDate":"2009-01","conditions":"Sepsis","enrollment":60},{"nctId":"NCT00754273","phase":"","title":"An Evaluation Of Respiratory Samples for Staphylococcus Resistance PatternsS","status":"COMPLETED","sponsor":"University of Kentucky","startDate":"2008-09","conditions":"Methicillin-resistant Staphylococcal Aureus Pneumonia","enrollment":1250},{"nctId":"NCT00572559","phase":"PHASE4","title":"Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-11","conditions":"Pneumonia, Ventilator-Associated","enrollment":149},{"nctId":"NCT00035425","phase":"PHASE3","title":"Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-11","conditions":"Febrile Neutropenia","enrollment":120},{"nctId":"NCT00037050","phase":"PHASE3","title":"Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-04","conditions":"Bacterial Infections, Gram-Positive Bacterial Infections, Bacteremia","enrollment":739},{"nctId":"NCT00035854","phase":"PHASE3","title":"New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-02","conditions":"Bacterial Infections","enrollment":13},{"nctId":"NCT00435305","phase":"","title":"Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion","status":"TERMINATED","sponsor":"University Hospital Tuebingen","startDate":"2006-11","conditions":"Pneumonia, Bacteremia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"HAEMORRHAGE"}],"_approvalHistory":[],"publicationCount":372,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vancomycin / Linezolid","genericName":"Vancomycin / Linezolid","companyName":"Durata Therapeutics Inc., an affiliate of Allergan plc","companyId":"durata-therapeutics-inc-an-affiliate-of-allergan-plc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin inhibits cell wall synthesis in Gram-positive bacteria, while Linezolid inhibits protein synthesis by binding to the 50S ribosomal subunit. Used for Treatment of complicated skin and skin structure infections (cSSSI), including those caused by susceptible Gram-positive bacteria, Treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}